Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bempegaldesleukin + atezolizumab
- Development stage
- Discontinued
- Lead developer
- Nektar Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bempegaldesleukin + atezolizumab is an experimental **combination immunotherapy** consisting of bempegaldesleukin (a PEGylated interleukin-2, code name NKTR-214) and atezolizumab (a monoclonal antibody targeting programmed death-ligand 1, PD-L1). Bempegaldesleukin selectively activates the IL-2 pathway through CD122, resulting in the proliferation and activation of CD8+ T cells and natural killer (NK) cells while minimizing expansion of regulatory T cells. Atezolizumab inhibits the PD-L1 immune checkpoint pathway, thereby restoring anti-tumor T cell activity. The combination is intended to leverage synergistic effects by enhancing effector immune cell activity within the tumor microenvironment and simultaneously releasing immune inhibition. Both agents are being developed primarily for advanced and metastatic solid tumors, though the clinical status of this specific combination is investigational.
- Other names
- bempegaldesleukin + atezolizumab
02
Targets
IL2RB (IL-2 receptor beta chain)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on bempegaldesleukin + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bempegaldesleukin + atezolizumab.